Therefore, studies to evaluate the efficacy of treatments for CRLF2 B-ALL are typically conducted in the context of JAK mutations and without TSLP-induced CRLF2 signals [30]. This evidence concerns the gene CRLF2 and acute lymphoblastic leukemia.